Abebaw Nigusie, Biset Gebeyaw, Yimer Nega, Gezie Hailemariyam, Workneh Moges, Mulugeta Chalie, Emagneneh Tadele, Alamrew Abebaw, Birhan Zelalem
Department of Midwifery, College of Medicine and Health Science, Wollo University, Dessie, Ethiopia.
Department of Pediatrics and Child Health, College of Medicine and Health Science, Wollo University, Dessie, Ethiopia.
Front Oncol. 2025 May 29;15:1515246. doi: 10.3389/fonc.2025.1515246. eCollection 2025.
The term of gestational trophoblastic disease (GTD) is used to describe a group of tumors that are characterized by abnormal trophoblastic proliferation. Histologically, GTD includes the pre-malignant partial hydatidiform mole, complete hydatidiform mole, and malignant invasive moles that are choriocarcinoma, placental site trophoblastic tumors, and epithelioid trophoblastic tumors.
The protocol for this review was registered on PROSPERO, accessible at CRD42024560408. We used the "PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews and Meta-analysis. All original and published cross-sectional, cohort, and case-control types of studies were reported during the study period. Studies conducted in both community and institutional settings were considered. Two reviewers independently assessed the risk of bias in the included studies using tools developed by the Joanna Briggs Institute, which comprise eight criteria.
Data was systematically searched by Google Scholar ( = 214), HINARI ( = 46), Scopus ( = 40), and PubMed ( = 146) on 1 May 2024. A total of 13 studies from five countries in East Africa have been included. The random effects model showed that the prevalence of GTD among pregnant women was 22% (95% CI: 10%-33%). Women who are aged between 30 and 39 years (AOR = 0.11, 95% CI: 0.05-0.16), women who have a previous history of GTD (AOR = 0.24, 95% CI: 0.00-0.47), women who have a previous complication of the reproductive organ system (AOR = 0.23, 95% CI: 0.10-0.35), and women who have more than two histories of pregnancy (AOR = 0.9, 95% CI: 0.06-0.11) were significantly associated with the outcome variable.
This finding revealed that the pooled prevalence of GTD among pregnant women was high. Women who are aged between 30 and 39 years, have a previous history of GTD, and women who have had previous complications during pregnancy, and women who have more than two histories of pregnancy were significantly associated with the outcome variable.
妊娠滋养细胞疾病（GTD）一词用于描述一组以滋养细胞异常增殖为特征的肿瘤。从组织学上看，GTD包括癌前部分性葡萄胎、完全性葡萄胎以及恶性侵袭性葡萄胎，即绒毛膜癌、胎盘部位滋养细胞肿瘤和上皮样滋养细胞肿瘤。
本综述方案已在PROSPERO注册，可通过CRD42024560408访问。我们采用了“PRISMA 2020声明：系统评价和荟萃分析报告的更新指南”。在研究期间报告了所有原始和已发表的横断面、队列和病例对照研究类型。考虑了在社区和机构环境中进行的研究。两名评审员使用乔安娜·布里格斯研究所开发的工具（包括八个标准）独立评估纳入研究的偏倚风险。
2024年5月1日通过谷歌学术搜索（=214）、HINARI（=46）、Scopus（=40）和PubMed（=146）系统检索数据。共纳入了来自东非五个国家的13项研究。随机效应模型显示，孕妇中GTD的患病率为22%（95%置信区间：10%-33%）。年龄在30至39岁之间的女性（比值比=0.11，95%置信区间：0.05-0.16）、有GTD既往史的女性（比值比=0.24，95%置信区间：0.00-0.47）、有生殖器官系统既往并发症的女性（比值比=0.23，95%置信区间：0.10-0.35）以及有两次以上妊娠史的女性（比值比=0.9，95%置信区间：0.06-0.11）与结局变量显著相关。
这一发现表明，孕妇中GTD的合并患病率较高。年龄在30至39岁之间、有GTD既往史、孕期有既往并发症以及有两次以上妊娠史的女性与结局变量显著相关。
